364 related articles for article (PubMed ID: 38449313)
1. Engineering small-molecule and protein drugs for targeting bone tumors.
Wang Y; Wang C; Xia M; Tian Z; Zhou J; Berger JM; Zhang XH; Xiao H
Mol Ther; 2024 May; 32(5):1219-1237. PubMed ID: 38449313
[TBL] [Abstract][Full Text] [Related]
2. New Insights about the Wnt/β-Catenin Signaling Pathway in Primary Bone Tumors and Their Microenvironment: A Promising Target to Develop Therapeutic Strategies?
Danieau G; Morice S; Rédini F; Verrecchia F; Royer BB
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31370265
[TBL] [Abstract][Full Text] [Related]
3. Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model.
Rudnick-Glick S; Corem-Salkmon E; Grinberg I; Margel S
J Nanobiotechnology; 2016 Dec; 14(1):80. PubMed ID: 27919267
[TBL] [Abstract][Full Text] [Related]
4. Drugs targeting the bone microenvironment: new therapeutic tools in Ewing's sarcoma?
Redini F; Odri GA; Picarda G; Gaspar N; Heymann MF; Corradini N; Heymann D
Expert Opin Emerg Drugs; 2013 Sep; 18(3):339-52. PubMed ID: 23957761
[TBL] [Abstract][Full Text] [Related]
5. Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma.
Shaikh AB; Li F; Li M; He B; He X; Chen G; Guo B; Li D; Jiang F; Dang L; Zheng S; Liang C; Liu J; Lu C; Liu B; Lu J; Wang L; Lu A; Zhang G
Int J Mol Sci; 2016 Apr; 17(4):506. PubMed ID: 27058531
[TBL] [Abstract][Full Text] [Related]
6. Potential of targeted drug delivery system for the treatment of bone metastasis.
Vinay R; KusumDevi V
Drug Deliv; 2016; 23(1):21-9. PubMed ID: 24839990
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy in the management of osteosarcoma and Ewing's sarcoma.
Schuetze SM
J Natl Compr Canc Netw; 2007 Apr; 5(4):449-55. PubMed ID: 17442235
[TBL] [Abstract][Full Text] [Related]
8. Bone-specific drug delivery systems: approaches via chemical modification of bone-seeking agents.
Hirabayashi H; Fujisaki J
Clin Pharmacokinet; 2003; 42(15):1319-30. PubMed ID: 14674786
[TBL] [Abstract][Full Text] [Related]
9. Targeting anti-cancer agents to bone using bisphosphonates.
Xing L; Ebetino FH; Boeckman RK; Srinivasan V; Tao J; Sawyer TK; Li J; Yao Z; Boyce BF
Bone; 2020 Sep; 138():115492. PubMed ID: 32585321
[TBL] [Abstract][Full Text] [Related]
10. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
Dos Santos MP; de Farias CB; Roesler R; Brunetto AL; Abujamra AL
Oncol Rep; 2014 Feb; 31(2):955-68. PubMed ID: 24316794
[TBL] [Abstract][Full Text] [Related]
11. Bisphosphonate-functionalized micelles for targeted delivery of curcumin to metastatic bone cancer.
Kamble S; Varamini P; Müllner M; Pelras T; Rohanizadeh R
Pharm Dev Technol; 2020 Nov; 25(9):1118-1126. PubMed ID: 32686553
[TBL] [Abstract][Full Text] [Related]
12. Investigational therapies for Ewing sarcoma: a search without a clear finding.
Vornicova O; Bar-Sela G
Expert Opin Investig Drugs; 2016 Jun; 25(6):679-86. PubMed ID: 26988130
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells.
Scotlandi K; Perdichizzi S; Manara MC; Serra M; Benini S; Cerisano V; Strammiello R; Mercuri M; Reverter-Branchat G; Faircloth G; D'Incalci M; Picci P
Clin Cancer Res; 2002 Dec; 8(12):3893-903. PubMed ID: 12473605
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for the treatment of bone metastasis.
Pantano F; Iuliani M; Zoccoli A; Fioramonti M; De Lisi D; Fioroni I; Ribelli G; Santoni M; Vincenzi B; Tonini G; Santini D
Expert Opin Emerg Drugs; 2015; 20(4):637-51. PubMed ID: 26113304
[TBL] [Abstract][Full Text] [Related]
15. Prospects and challenges for the development of new therapies for Ewing sarcoma.
Grohar PJ; Helman LJ
Pharmacol Ther; 2013 Feb; 137(2):216-24. PubMed ID: 23085431
[TBL] [Abstract][Full Text] [Related]
16. Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma).
Anderson P; Kopp L; Anderson N; Cornelius K; Herzog C; Hughes D; Huh W
Expert Opin Investig Drugs; 2008 Nov; 17(11):1703-15. PubMed ID: 18922107
[TBL] [Abstract][Full Text] [Related]
17. Engineered nanomedicine for myeloma and bone microenvironment targeting.
Swami A; Reagan MR; Basto P; Mishima Y; Kamaly N; Glavey S; Zhang S; Moschetta M; Seevaratnam D; Zhang Y; Liu J; Memarzadeh M; Wu J; Manier S; Shi J; Bertrand N; Lu ZN; Nagano K; Baron R; Sacco A; Roccaro AM; Farokhzad OC; Ghobrial IM
Proc Natl Acad Sci U S A; 2014 Jul; 111(28):10287-92. PubMed ID: 24982170
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-based therapy in pediatric bone tumors: how to overcome resistance.
Guiho R; Biteau K; Heymann D; Redini F
Future Oncol; 2015; 11(3):535-42. PubMed ID: 25675131
[TBL] [Abstract][Full Text] [Related]
19. [Pre- and postoperative chemotherapy in bone and soft tissue tumors].
Höffken K
Langenbecks Arch Chir; 1987; 372():311-4. PubMed ID: 3481009
[TBL] [Abstract][Full Text] [Related]
20. Experiments and synthesis of bone-targeting epirubicin with the water-soluble macromolecular drug delivery systems of oxidized-dextran.
Yu L; Cai L; Hu H; Zhang Y
J Drug Target; 2014 May; 22(4):343-51. PubMed ID: 24405056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
